ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Biosynthesis, characterization, and antiproliferative activity of gold nanoparticles synthesized using Artemisia chamaemelifolia extract against cisplatin-resistant ovarian cancer cells.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer remains a major clinical challenge, largely because many patients eventually develop resistance to cisplatin. In this study, gold nanoparticles (AuNPs) were synthesized using Artemisia chamaemelifolia extract through a green chemistry approach, and their antiproliferative activity was evaluated in cisplatin-resistant A2780cp ovarian cancer cells.
methodsThe aqueous extract of the plant was used as both the reducing and stabilizing agent during nanoparticle formation. The synthesized AuNPs were characterized using UV-Vis spectroscopy, FTIR, FESEM, TEM, and DLS. Cytotoxic effects were assessed using the MTT assay, while apoptosis was evaluated by Annexin V/PI flow cytometry. Changes in the expression of BAX, BCL-2, TP53, and CCND1 were assessed by RT-qPCR. HEK293 cells were included as a comparator cell line for cytotoxicity.
resultsUV-Vis spectroscopy showed a surface plasmon resonance peak near 530 nm, confirming nanoparticle formation. FESEM and TEM analyses revealed well-dispersed nanoparticles with predominantly spherical to slightly cubic morphology, an average size of 15.13 nm, and a relatively narrow size distribution. The MTT assay demonstrated dose-dependent cytotoxicity, with an IC₅₀ of 38.83 µg/mL(95% CI: 31.85 to 47.28) in A2780cp cells and no IC₅₀ reached within the tested concentration range for HEK293 cells (n = 3). Accordingly, the selectivity index (SI) was estimated to be > 5.15, suggesting preferential cytotoxicity toward A2780cp cells. In contrast, cisplatin showed a lower SI of 1.24. Flow cytometry indicated an increase in early apoptotic cells from 16.1 ± 1.2% to 69.2 ± 3.4% (n = 3), accompanied by a reduction in overall viability. RT-qPCR results were consistent with these findings, showing upregulation of BAX and TP53 and downregulation of BCL-2 and CCND1.
conclusionAuNPs synthesized by this green method exhibited selective cytotoxic and pro-apoptotic activity against cisplatin-resistant ovarian cancer cells. These findings suggest their potential as a biocompatible candidate in strategies aimed at addressing chemoresistance in ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.